To investigate if people with subjective memory complaints (SMC) but no objective deficits are at increased risk of developing mild cognitive impairment (MCI) and dementia.
Introduction
Subjective memory complaints (SMC) are everyday memory and related cognitive concerns expressed by people who may or may not have deficits on objective testing. Although a definition of SMC has not been operationalized 1 numerous self-report measures have been developed. 2 In one large community survey about half of individuals reported minor memory problems. 3 In a UK survey, 31.7% reported forgetfulness in the last month, while 6.4% had forgotten something important in the last week. 4 A meta-analysis found that SMC were present in about 17% elderly people with no objective deficits. 5 The presence of SMC is associated with distress, reduced mental health, wellbeing and quality of life 6 and difficulties undertaking activities of daily living. 7 SMC also appears to be a risk factor for nursing home placement 8 , future mortality 9 and is associated with increased healthcare costs. 10 However, perceived memory complaints may not always be a sinister finding since only a small proportion of memory complaints are severe enough to interfere with daily life and many with SMC do not deteriorate more rapidly than usual. 11 12 13 In addition, psychological factors such as depression influence
The primary aim of this study was to investigate the annual conversion rate (ACR) of people with SMC to a) MCI and b) dementia in prospective longitudinal studies. The secondary aim was to establish the cumulative proportion of those with SMC who progressed to a) MCI and b) dementia over the course of follow up. In addition, we sought to investigate if the conversion rates differed according to baseline objective cognitive testing, follow-up duration and recruitment setting. Finally, we calculated relative risks (RR) comparing the progression to dementia in people with and without SMC at baseline (where both subgroups were recruited from the same centre).
Methods
This systematic review is conducted in accordance with the MOOSE guidelines 29 following a predetermined protocol.
Inclusion and Exclusion
Studies were eligible that 1) included people with reported SMC at baseline, with or without a control group that did not have SMC. 2) Were prospective longitudinal studies with a follow up of at least 6 months 3)
Measured objective cognitive performance including criteria for either MCI and/ or dementia (of any type) as an end point of the study using recognized diagnostic criteria (ICD10, or DSM IV). If we identified studies that appeared eligible but did not report the variables of interest, the protocol stipulated that we contacted the corresponding authors in order to ascertain these. We did not place any language restriction upon the eligibility of the searches. If we encountered multiple studies from the same data set we included the largest study and/ or the study with the longest follow up period. Studies were excluded that included participants at baseline that all had objective cognitive impairment. We excluded studies that did not report the proportion of subjects with cognitive decline (for example those that reported means alone).
Three authors (HB, BS, AJM) independently extracted data from all eligible studies using a predetermined form (Available upon request from the corresponding author). If any discrepancies were identified these resolved through discussion and with reference to the original manuscript and if necessary contact with the corresponding authors of the original articles. The data collected from each manuscript included details of the study (including year, setting, time of follow up) and participant demographics (number at baseline, mean age, % female), details of how SMC was measured/ defined, the method of cognitive assessment and diagnosis of MCI and dementia (including type). In addition, we extracted data on the number of people that progressed to MCI and dementia in each cohort and also those who were lost in follow up.
Meta-Analysis
We used the method previously described in a similar study from our group. 30 Our main analysis was the pooled annual conversion rate (ACR) which is calculated by dividing the number of cases who progresses by the person years of observation in each type of study. Each studies ACR was pooled in a meta-analysis which weighted for both study size and follow-up (person years). This statistic tells the reader/clinician: how many similar patients would typically progress each year. A secondary analysis was the cumulative progression which uncorrected for years of observation. This statistic tells the reader/clinician: how many similar patients would typically progress over time. We calculated rates of progression as a proportion of those recruited at baseline (inception cohort method) rather than those that survived to follow-up, since this most closely resembles clinical practice when attempting to give estimates of prognosis. In addition very few studies provided information on drop-outs. We also calculated person years of observation in each type of study. Weighted proportion meta-analysis was used to adjust for study size using the DerSimonian-Laird model and to account for the anticipated heterogeneity. 31 In order to establish if people with SMC at baseline were more likely than those without SMC to develop dementia we calculated the relative risks (RR). We stratified the results and conducted subgroup analysis to see if the results differed when we only included studies without abnormal cognitive function at baseline, those with long (4> years) and in those in community or specialist settings. The I 2 statistic was calculated for each analysis to determine heterogeneity. 32 In order assess the risk of bias we undertook a visual inspection of funnel plots and calculated the Harbord bias test.
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Results

Study selection, Study and participant characteristics
From a total of 111 valid hits, we considered the full texts of 79 articles. At the full text review stage 47 articles were excluded with reasons and 32 articles were included in the systematic review. The full search strategy including the reasons for exclusion at the full text review is represented in figure 1 . 
Insert table 1 about here
Meta-analysis of the progression from SMC to mild cognitive impairment
Annual Conversion Rate
Data from 11 studies 43 Meta-analysis of the progression from individuals without SMC to dementia (healthy controls)
From 14 studies involving healthy older adult controls without SMC and without objective cognitive complaints the pooled ACR was 1.00% (95% CI = 0.71% to 1.34%). There was high heterogeneity (I² = 93.1%, 95% CI = 90.5% to 94.6%) and no indication of publication bias (Harbord bias = 0.558, P = 0.741).
Cumulative Conversion Proportion
Across 14 studies involving 14,949 healthy older controls without SMC and without objective complaints that were conducted over four years established that 4.6% (95% CI = 2.8% to 6.9%) of participants developed dementia. The data was heterogeneous (I² = 96.3% (95% CI = 95.3% to 96.9%) but there was no evidence of publication bias (Harbord bias= -2.3, P = 0.39).
Meta-analysis of the progression from SMC to dementia
Annual Conversion Rate
28 studies examined progression of SMC to dementia representing 86,200 person years of observation. The ACR of people with SMC developing dementia was 2.33% (95% CI = 1.93% to 2.78%) (figure 3). There was high heterogeneity (I² = 89.2%; 95% CI = 86% to 91.4%) and some evidence of publication bias (Harbord: bias = 2.55 P = 0.01) but the funnel plot was symmetrical (figure 2b).
Insert figure 3 about here 2. Cumulative Conversion Proportion from SMC to dementia
From 28 studies 34-61 10.99% (95% CI = 8.20 to 14.12) of those with SMC developed dementia over the course of the follow up period of 4.8 years. There was high heterogeneity (I² = 95.4%, 95% CI = 94.6% to 96.1%) but the funnel plot was symmetrical and the Harbord bias test did not indicate any evidence of publication bias (-0.7154, P = 0.64).
Subgroup analysis of progression of SMC to dementia
From 21 studies conducted in the community the cumulative conversion from SMC to dementia was 10.79%
(95% CI 7.7 to 14.3, I² = 96.4%, Harbord: bias = -1.10 P = 0.6101) over a mean of 5.2 years. The cumulative proportion of people with SMC that developed dementia in specialist settings was 11.7% (95% CI = 5.0 to 20.7, I² = 83.8%, Harbord: bias = -2.20 P = 0.5378) over a mean of 3.2 years. After correcting for follow-up duration, the ACR for community studies was 2.2% (95% CI = 1.8% to 2.6%) and 3.2% (95% CI = 1.1% to 6.3% in specialist non-community studies it was). 
Meta-analysis comparing the risk of developing dementia in people with and without SMC
It was possible to compare the risk for developing dementia in people with and without SMC using data from 14 studies, over a mean follow up of 4.94 years. The pooled RR was 2.07 (95% CI = 1.77 to 2.44) establishing that people with SMC (n=3,821) were twice more likely than those without SMC (n=15,009) to develop dementia (figure 4). The data was not heterogeneous (I² = 17.5% (95% CI = 0% to 56.2%) and there was no evidence of publication bias (Harbord = 0.93, P = 0.08).
Insert figure 4 here
Discussion
To our knowledge this is the first study to perform a quantitative data synthesis of studies reporting rates of progression of those with SMC to MCI and dementia. When considering dementia, we included 28 robust cohort studies and found that the overall ACR rate among 86,200 person years of observation was 2.33% in those with SMC at baseline compared to 1% in those without SMC. This represents a twofold increased risk of developing dementia in those with vs without SMC (RR 2.07, 95% CI= 1.77 to 2.44, p<0.001).
The overall proportion that converted to dementia from 28 studies was 10.99% over the follow up period of about 5 years although it was 14% in long term studies that followed participants over a mean of 6.8 years.
When we conducted subgroup analyses comparing studies in community or specialist non-community settings (mainly memory clinics) we found cumulative conversion rates from SMC to dementia at 10.7% over 5. These results may be supported by longitudinal biological studies showing SMC at baseline is linked with subsequent change in hippocampal volume. 80 Awareness of cognitive deficits has a u-shaped distribution being low with mild complaints, rising but then generally low with severe cognitive impairment. 81 82 83 84 85 Insight is usually preserved in mild dementia and in mild cognitive impairment (MCI). 86 Our findings in relation to SMC should be considered in the context of previously reported research in relation to MCI. In the case of MCI, Mitchell and Feshki found an ACR of 6.7%
(95% CI = 4.6-9.1%) and a RR of 13.8 (95% CI = 8.44-22.6) in relation to progression of MCI to dementia. 30 Thus SMC are a much lower risk of progression than MCI (about 1/3 numerically) but still clearly important. SMC forms a core component of the criteria for MCI. 87 88 It may be therefore than SMC contributes part of the significance of MCI but MCI and SMC are not synonymous prognostically. 89 A key issue for MCI is that function must be unimpaired or minimally impaired in current guidelines. However impaired function can co-occur with SMC even in the absence of objective impairment. Data from the Spanish Neurological Diseases in Central Spain study (NEDICES) cohort involving 1,073 participants found that of 730 with pure SMC, 18.1% had significantly impaired function and 9.5% had severely impaired function measured by the Pfeffer scale. 90 It is likely that SMC and function are independent predictors of decline, but this requires further study.
Our results suggest that SMC should not merely be considered as a benign age related phenomenon since our meta-analysis demonstrates that those with SMC are at significantly increased risk of future cognitive decline, particularly of MCI. Yet there is considerable heterogeneity in samples with SMC. For example types of complaints may vary in mid-life vs late life. 91 Community dwelling participants with no functional limitation but isolated SMC are likely to be quite different from memory clinic attendees with SMC. We found that there were comparable cumulative proportions with SMC that converted to dementia in community or specialist settings (10.7% and 11.7% respectively) although the mean follow up for community settings was two years less in on average (5.2 v 3.2 years) and is therefore of little surprise. When we investigated the ACR from SMC to dementia this was comparable for community settings (2.2%) and non-community settings (3.2%).
Although we found that 34.2% of people with SMC converted to MCI in community settings compared to 16.5% in specialist settings after correcting for follow-up the ACR the results were similar (7.7% and 5.6% respectively).
The similarities in ACR according to setting are likely to be because the subgroup analysis were underpowered.
Clinically the approach to the management of SMC may have to be revised in light of these findings. SMC may be amenable to treatment in the absence of objective decline 92 and the next step is to study whether amelioration of SMC at early stage influences the rate of progression of cognitive decline.
We wish to acknowledge the following limitations. We had limited access to younger samples. As a result the prognosis of SMC in mid-life is uncertain. We were unable to stratify outcomes by types of dementia. This could be important as certain dementias may be more strongly liked with a long-prodromal period and high perceived subjective decline. In addition, due to limitations in the data it was not possible to establish if the method of diagnosing dementia (e.g. DSM-IV or ICD 10) influenced our results. Therefore, future research should investigate this. Another important limitation is that as expected, the studies included in our review adopted a wide range of methods to capture SMC, which is difficult to overcome since there is currently no gold standard to define SMC. Heterogeneity and lack of reporting of exact methods in primary studies prevented us from conducting subgroup analysis to see if the method of defining SMC affects the conversion rates to MCI and dementia. This is therefore another recommended topic for future research. We had modest duration of follow-up with a maximum of 8 years. It is therefore unknown whether the rate of progression accelerates, stays stable or declines with time. It is important to also note that almost all of the results within our review had substantial heterogeneity. Finally in some cases there was evidence of publication bias.
Conclusion
SMC may be a clinically meaningful indicator of future cognitive decline, with individuals experiencing SMC at increased risk of developing MCI and dementia. However the context and setting of the SMC report remains important.
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